Chronic myelogenous leukemia (CML) Drug Development Opportunities

Standard

Ajoutez votre grain de sel personnel… (facultatif)

Hoffmann & Krueger Oncology Excellence

Leukemia is the neoplastic proliferation of the hematopoietic cells. These cells are undifferentiated or partially differentiated stages of maturation. As a consequence of the immature leukocytes excessive proliferation, these cells eventually replace the normal blood-forming elements, resulting in the patient presenting with clinical and laboratory evidence of leukopenia, anemia, and thrombocytopenia.

 

In terms of incidence, chronic myelogenous leukemia (CML) is the second most frequent form of myeloid leukemia after acute myeloid leukemia (AML), accounting for approximately the third of all incident cases of myeloid leukemias. However, the CML prognosis is good, resulting in the number of prevalent cases of CML outnumbering those of AML based on survival data analysis from the United States (SEER, 2011). Although, the risk of developing CML is very low, its status as a chronic disease implies a disproportionately large burden of disease and period of treatment, with many CML patients being maintained on a…

View original post 1,220 more words

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s